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The incidence of flavivirus infections has increased dramatically in recent decades
in tropical and sub-tropical climates worldwide, affecting hundreds of millions of
people each year. The Flaviviridae family includes dengue, West Nile, Zika, Japanese
encephalitis, and yellow fever viruses that are typically transmitted by mosquitoes or
ticks, and cause a wide range of symptoms, such as fever, shock, meningitis, paralysis,
birth defects, and death. The flavivirus genome is composed of a single positive-sense
RNA molecule encoding a single viral polyprotein. This polyprotein is further processed
by viral and host proteases into three structural proteins (C, prM/M, E) and seven non-
structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5) that are involved in
viral replication and pathogenicity. The complement system has been described to play
an important role in flavivirus infection either by protecting the host and/or by influencing
disease pathogenesis. In this mini-review, we will explore the role of complement system
inhibition and/or activation against infection by the Flavivirus genus, with an emphasis
on dengue and West Nile viruses.
Keywords: complement system, flavivirus, dengue, NS1 protein, immune evasion
INTRODUCTION
The Flaviviridae family consists of many viral pathogens that cause severe disease and mortality
in humans and animals. The family consists of four genera: Flavivirus, Pestivirus, Pegvirus, and
Hepacivirus. In this mini-review, we will focus on the Flavivirus genus, which is the largest of
the four genera, comprising more than 70 viruses, including dengue (DENV), West Nile (WNV),
Zika (ZIKV), Japanese encephalitis (JEV), yellow fever (YFV), St. Louis encephalitis (SLEV), and
tick-borne encephalitis (TBE) viruses (Lindenbach and Rice, 2003). The flaviviruses are primarily
transmitted by arthropods such as mosquitoes and ticks. The most common mode of biological
transmission is infection during a viremic blood meal and injection of infectious saliva during
blood feeding (Kuno and Chang, 2005).
The rate of flavivirus infections worldwide has increased dramatically in the last few years,
with the resurgence of all DENV serotypes (DENV1-4), WNV, YFV, and the emergence of ZIKV,
affecting hundreds of millions of people each year (Gubler, 1998, 2002, 2007; Bhatt et al., 2013;
Chan, 2016; Musso and Gubler, 2016). The large geographical expansion of flaviviruses has been
related to vector adaptation of Aedes aegypti and A. albopictus to domesticated environments
(Kuno and Chang, 2005). Other factors such as climate and genetic changes, global growth of
human populations with extensive urbanization, lack of effective mosquito control, and increased
air travel have also been associated with the emergence of flaviviruses (Gubler, 2002; Bennett et al.,
2003; Steel et al., 2010; Weaver and Reisen, 2010).
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Although most people infected with flaviviruses develop
asymptomatic infection, the clinical spectrum is broad. After
incubation for 3–6 days, there is an abrupt onset of many
symptoms including high fever, chills, headache, back and muscle
aches, dizziness, anorexia, nausea, and vomiting (Gould and
Solomon, 2008; Murphy and Whitehead, 2011). Patients infected
with one of the four DENV serotypes can develop severe
manifestations that are characteristic of dengue hemorrhagic
fever (DHF) and dengue shock syndrome (DSS), such as vascular
leakage, that can lead to hypovolemic shock, coagulopathy that
can be accompanied by bleeding, organ impairment and death
(Simmons et al., 2012). Severe disease is associated frequently
with secondary infection with a different serotype and primary
infections of infants born to DENV-immune mothers. At
concentrations that do not reach the stoichiometric threshold
necessary for neutralization, anti-flavivirus antibodies enhance
infection in cells expressing Fc-γR, a phenomenon known as
antibody-dependent enhancement (ADE; Halstead et al., 2005;
Pierson et al., 2007). Together with two additional non-exclusive
hypotheses of viral virulence and serotype-cross-reactive memory
T cells, these three processes could lead to excessive complement
activation and cytokine release, resulting in DHF/DSS (Balsitis
et al., 2010; Zellweger et al., 2010; Rothman, 2011).
In addition, humans infected with WNV develop
meningitis or encephalitis syndrome that could be fatal in
immunocompromised patients (Granwehr et al., 2004), while
ZIKV infections may cause neurological complications such as
microcephaly in neonates and Guillain–Barré syndrome in adults
(Musso and Gubler, 2016). Because these severe manifestations
occur relatively late during the course of disease when the virus
may no longer be detectable in plasma, mechanisms mediated
by immune responses may play a significant role in pathogenesis
(Simmons et al., 2012).
FLAVIVIRUS STRUCTURE
Flavivirus virions are ∼500 Å in diameter and are composed
of a single positive-strand RNA genome, that is packaged by
the viral capsid protein (C) in a host-derived lipid bilayer
and surrounded by 180 copies of two structural proteins,
envelope (E) and membrane (M, which is expressed as the
precursor prM; Lindenbach and Rice, 2003; Mukhopadhyay et al.,
2005). The genome is translated into a single polyprotein, and
subsequently cleaved by viral and host proteases into three
structural proteins (C, prM/M, and E) and seven non-structural
(NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5;
Lindenbach and Rice, 2003). The E protein functions in receptor
binding, viral entry, and membrane fusion and elicits most
neutralizing antibodies, whereas prM assists in folding, assembly,
and function of the E protein (Lindenbach and Rice, 2003).
The NS proteins regulate RNA transcription and replication as
well as evasion and attenuation of the host immune response
(Lindenbach and Rice, 2003; Dalrymple et al., 2015). Viral
particles assemble at the endoplasmic reticulum (ER) and are
released by exocytosis following transport through the trans-
Golgi network (Mukhopadhyay et al., 2005).
COMPLEMENT SYSTEM AND
FLAVIVIRUSES
Pathogenic Effects of Complement
Activation during Flavivirus Infections
The complement system is composed of more than 50 plasma
proteins and receptors. Several complement proteins found in
the blood normally circulate as inactive precursors and, once
activated, they initiate a proteolytic cascade, resulting in release
of chemokines, opsonization, and deposition of the cell-killing
membrane attack complex (MAC; Merle et al., 2015a). Activation
of the complement system occurs via three convergent pathways,
the classical, the lectin, and the alternative pathways. The
classical pathway is initiated by C1q binding to antigen-antibody
complexes on the surface of pathogens or by direct binding
of C1q to pathogen protein, or to the virion itself (Thielens
et al., 2002). The lectin pathway is triggered by mannose-binding
lectin (MBL) or ficolin recognition of carbohydrates on cell
surfaces. The alternative pathway is constitutively activated at
low concentrations through spontaneous hydrolysis of C3 and
serves to amplify activation triggered by the classical and lectin
pathways (Merle et al., 2015a). Binding of C3b to C3 convertases
generates C5 convertases, which cleave C5 into C5a and C5b. C5b
initiates the assembly of the MAC by interacting with C6, C7,
C8, and multiple C9 molecules in the membrane of the pathogen
(Merle et al., 2015a).
The complement system has an antagonistic role in flavivirus
infections, either by limiting viral replication and protecting
the host or by causing an exacerbated inflammatory response
when excessively activated, increasing disease severity (Shresta,
2012). The majority of studies have focused on the role of
complement in the context of DENV and WNV pathogenesis.
Initial in vitro studies showed that macrophage complement
receptors (CR3) mediate IgM-dependent increase of flavivirus
replication in the presence of complement, and a blockade
of CR3 abolishes complement-dependent enhancement of
WNV infection (Cardosa et al., 1983, 1986). During WNV
neuroinvasive disease, patients that survive often exhibit memory
impairment, an effect that was related to complement-mediated
elimination of presynaptic terminals (Vasek et al., 2016). C1q was
found upregulated and localized to microglia, infected neurons,
and presynaptic terminals during WNV infection, and mice
deficient in CR3 receptor were protected from WNV-induced
synaptic terminal loss (Vasek et al., 2016).
Moreover, clinical and in vivo studies showed that excessive
consumption of C3, C4, factor B and C5 contributed to DHF/DSS
and increased levels of the products of complement activation
(C3a, C5a) that contribute to histamine release, enhanced
vascular permeability and vasodilatation both in DENV and
WNV infections. Indeed, the anaphylatoxins concentration in the
blood of severe patients correlated with symptoms of vascular
leakage (Bokisch et al., 1973; Nishioka, 1974; Mehlhop and
Diamond, 2006; Nascimento et al., 2009; Pinto et al., 2014).
Furthermore, anti-DENV antibodies activated complement on
the surface of endothelial cells resulting in MAC formation
(Avirutnan et al., 1998). Another study showed that NS1, C3a,
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FIGURE 1 | Schematic illustration of complement activation and evasion by NS1 protein of flavivirus. NS1 is expressed on the surface (mNS1) and is also
secreted by flavivirus-infected cells (sNS1). Circulating sNS1 can subsequently bind to the surface of both infected and uninfected cells. In dengue virus secondary
infections, IgM and IgG antibodies to NS1 during the acute phase of the disease can lead to the formation of immune complexes (1) that trigger inflammatory
responses, including the activation of the complement cascade to generate the anaphylatoxins C3a and C5a, opsonins, and the membrane attack complex (MAC;
reviewed by Muller and Young, 2013) (2). NS1 has also been shown to contribute to viral immune evasion through interaction with complement proteins and its
regulators. Binding to the alternative complement pathway regulatory protein FH leads to accelerated breakdown of the alternative pathway convertase with
consequent reduced C3b deposition and MAC formation (Chung et al., 2006). NS1 also binds to proC1s/C1s and C4 which results in increased cleavage of C4 to
C4a and C4b, what may limit the amount of C4 available (Avirutnan et al., 2010). In addition, C4BP bound to NS1 can act as a cofactor for Factor I-mediated
cleavage of C4b to C4c and C4d. Deposition of the sNS1–C4BP complex on the cell surface could lead to inactivation of cell surface bound C4b thereby protecting
infected cells from complement mediated lysis (Avirutnan et al., 2011b). NS1 from DENV-infected insect cells binds MBL and may protect DENV from MBL-mediated
neutralization, suggesting a role for limiting complement activation at the site of the mosquito bite (Thiemmeca et al., 2016) (3). NS1 was suggested to inhibit MAC
formation by interacting with vitronectin (VN), clusterin, and the terminal complement protein C9 (Kurosu et al., 2007; Conde et al., 2016) (4).
C5a and soluble C5b-9 were present at higher levels in the
plasma of DHF patients before plasma leakage (Avirutnan et al.,
2006), supporting the hypothesis that exacerbated complement
activation influences disease severity. Moreover, gene expression
of the complement inhibitor CD59 was up-regulated more
strongly in peripheral blood mononuclear cells (PBMCs) from
non-severe dengue patients than in DHF patients (Ubol
et al., 2008). These studies suggest that complement activation,
and further cytokine induction may be important factors
that contribute to vascular leakage, which is characteristic of
DHF/DSS pathogenesis, even though the underlying mechanisms
are not well understood.
Protective Effects of Complement
Activation during Flavivirus Infections
The complement system plays a key role in protection against
viruses by diverse mechanisms: direct inactivation of virions by
MBL; recruitment and activation of monocytes and granulocytes
by the anaphylatoxins C3a and C5a; opsonization of viral
particles mediated by the proteolytic fragments of C3 (C3b,
iC3b, C3d, and C3dg), which facilitate clearance by cells that
express complement receptors; antigen uptake and presentation
facilitated by C3; and lysis of enveloped viral particles and
infected cells by the MAC (Stoermer and Morrison, 2011; Merle
et al., 2015b).
Several studies have shown a protective effect for complement
on flavivirus infection. In vitro assays assessed ADE of DENV
infection and showed that fresh serum could abolish ADE
(Mehlhop et al., 2007; Yamanaka et al., 2008). Further analysis
demonstrated that this inhibitory effect was C1q-dependent both
in vitro and in vivo and IgG subclass-specific, suggesting that
complement proteins could limit disease progression (Mehlhop
et al., 2007). In addition, C1q enhanced the neutralizing activity
of anti-WNV antibodies, and reduced the number of antibodies
required to bind the WNV virion and neutralize infectivity
(Mehlhop et al., 2009b). Another study demonstrated that C1q
binds directly to both the DENV E protein and the viral
particle, and when C1q was pre-incubated prior to DENV
infection of THP-1 cells, decreased viral infectivity was observed
(Douradinha et al., 2014). Proteomics data confirmed the binding
of several complement proteins, including C1q, C1s, C1r, C5, C9,
and mannan-binding lectin serine protease 1 (MASP1) on viral-
enriched fractions from DENV-infected patients and on domain
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III of the DENV E protein (Fragnoud et al., 2015; Huerta et al.,
2016).
Moreover, in vitro studies reported that serum complement
neutralizes both WNV in solution and WNV-infected cells
in an antibody-dependent manner (Mehlhop et al., 2005).
Neutralization by serum complement also occurred through
direct binding of MBL, which activated MASP2 and resulted
in further opsonisation of the virion surface, preventing viral
fusion with host membranes (Fuchs et al., 2010). Furthermore,
MBL but not C1q or C5 restricted infection of all DENV
serotypes by both complement-dependent and independent
mechanisms. Nevertheless, the neutralization was more efficient
with insect-derived virus than mammalian-derived virus. Further
analysis showed that MBL concentration in human blood
correlated directly with DENV neutralization, indicating that
polymorphisms in the MBL gene may have an impact on
DENV infection and severity (Avirutnan et al., 2011a). In
addition, in vivo studies suggested that all activation pathways
were required to restrict WNV infection in mice (Mehlhop
et al., 2005; Mehlhop and Diamond, 2006; Fuchs et al., 2011).
However, WNV neutralization occurred primarily through C5-
and MAC-independent mechanisms (Mehlhop et al., 2009a).
Therefore, opsonization may be the main mechanism of flavivirus
neutralization, as the efficiency of MAC formation may be limited
by the small surface area of exposed flavivirus membrane.
Complement Activation and Evasion by
NS1 Protein
Among the NS proteins, NS1 is the primary flavivirus protein
that is antagonistically related to both complement activation
and evasion. NS1 is a highly conserved glycoprotein with a
molecular weight of 46–55 kDa, depending on its glycosylation
status. After polyprotein processing, NS1 is translocated into
the lumen of the ER, released from E protein by ER resident
signal peptidase (Muller and Young, 2013; Zhang et al., 2016),
cleaved at its C-terminus by an unidentified ER host protease
(Falgout and Markoff, 1995), and glycosylated by the addition
of high-mannose carbohydrates (Pryor and Wright, 1994). After
a rapid dimerization, NS1 acquires a partially hydrophobic
behavior and associates with cell membranes. The atomic
resolution of dimeric DENV and WNV NS1 structures revealed
a hydrophobic region comprised of approximately the first
20 residues of each monomer that form the beta-roll domain
(Akey et al., 2014). Together with another hydrophobic region
150 residues downstream, these domains are postulated to
insert into membranes (Watterson et al., 2016). An alternative
mechanism through which DENV NS1 interacts with cell
membranes was described after the identification of a glycosyl-
phosphatidylinositol (GPI)-linked form (Jacobs et al., 2000).
Thereafter, NS1 traffics to multiple destinations, including
sites of viral replication complex and associated vesicle packets
(VPs; Mackenzie et al., 1996; Lindenbach and Rice, 1997;
Khromykh et al., 1999), the cell membrane (mNS1; Winkler et al.,
1989; Schlesinger et al., 1990), and the extracellular environment
through secretion (sNS1; Crooks et al., 1990, 1994; Flamand
et al., 1999). The secreted form of NS1 traffics through the Golgi
secretory pathway in mammalian cells, and the carbohydrate
moieties are processed to more complex sugars that are then
secreted as a soluble hexamer associated with lipids, with a
molecular weight of ∼300 kDa (Crooks et al., 1990, 1994;
Flamand et al., 1999; Gutsche et al., 2011). Secreted NS1 was
found circulating in the blood of flavivirus-infected patients at
high levels (Alcon et al., 2002) and servers as a primary biomarker
for diagnosis.
The NS1 protein has been studied by several groups, and a
wide variety of functions has been assigned to it. In the 1970s,
a DENV soluble complement fixing antigen (SCF) that was later
identified and confirmed to be NS1 was detected in infected
mice and cell culture (Brandt et al., 1970; McCloud et al., 1970;
Russell et al., 1970). Both mNS1 and sNS1 activated complement
in the presence of anti-serum, and sNS1 triggered complement
activation even in the absence of specific antibodies (Avirutnan
et al., 2006). High levels of NS1, C5a, and SC5b-9 were present
in pleural fluids from patients with DSS, and their presence
correlated with disease severity (Avirutnan et al., 2006).
In addition to complement activation and auto-immune
responses, co-administration of recombinant NS1 with DENV
in an animal model of the disease resulted in morbidity,
cytokine induction and endothelial barrier disruption (Beatty
et al., 2015). Another recent study demonstrated that DENV
NS1 binds TLR4 on the surface of CD14+ monocytes and
induces cellular activation, cytokine production and vascular
permeability, a similar response triggered by the bacterial
endotoxin LPS (Modhiran et al., 2015). Therefore, the effects
of NS1, combined with exacerbated immune responses, could
contribute to the disruption of endothelial cell layer integrity,
resulting in hemorrhage and vascular leakage, which are
characteristic of dengue and YFV (Monath and Barrett, 2003;
Basu and Chaturvedi, 2008). Such a combination may also
contribute to deregulation of the blood brain barrier, which is a
crucial component of the development of encephalitis caused by
WNV and JEV (Neal, 2014).
In response to antiviral mechanisms, viruses have evolved
specific strategies to avoid complement activation and
neutralization by producing or binding complement-regulatory
or complement-blocking molecules (Stoermer and Morrison,
2011; Merle et al., 2015b). Flavivirus NS1 has been described
as an immune evasion protein that can attenuate activation
of the classical, lectin and alternative pathways by interacting
with complement proteins and their regulators (Figure 1). It is
worth mentioning that these interactions were not confirmed
experimentally for all flavivirus and may be specific for certain
viruses. WNV NS1 has been shown to bind Factor H (FH), and
bound FH retains cofactor activity for Factor I-mediated cleavage
of C3b to iC3b. In addition, cell membrane-associated NS1 also
recruits FH and consequently leads to a decreased deposition of
C3b and the MAC on cell surfaces (Chung et al., 2006). DENV,
WNV, and YFV also bind C4 and C1s/proC1s in a complex to
cleave C4 to C4b in solution, thus reducing the deposition of C4b
on cell surfaces and the activity of the classical C3 convertase
(C4b2a) (Avirutnan et al., 2010). C4b Binding Protein (C4BP),
which regulates both the classical and the lectin pathways of
complement, was also recruited by DENV, WNV, and YFV
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NS1. Once bound to NS1, C4BP, as a cofactor for FI, mediates
inactivation of C4b in solution and on the plasma membrane of
cells (Avirutnan et al., 2011b). FH, C1s, and C4BP have cysteine-
rich domains called complement control protein (CCP) domains.
Some proteins from different pathogens have been shown to
interact with CCP domains via an anti-parallel β-sheet motif
(Persson et al., 2007; Schneider et al., 2009; Bhattacharjee et al.,
2013). Thus the β-roll and β-ladder domains of NS1, which have
an anti-parallel β-sheet folding, are proposed to be candidates for
binding to complement proteins (Akey et al., 2015). Also, NS1
from DENV-infected insect cells binds MBL to protect DENV
from MBL-mediated neutralization, suggesting a role for limiting
complement activation at the site of mosquito bite (Thiemmeca
et al., 2016).
Through a yeast two-hybrid approach using a human liver
cDNA library, C1q was identified as a DENV NS1-binding
partner (Silva et al., 2013). However, it is unclear whether this
interaction contributes to complement activation or complement
evasion. DENV sNS1 has also been reported to bind complement
proteins from the terminal pathway. Clusterin, which inhibits
the formation of the MAC, is among the NS1 targets (Kurosu
et al., 2007), although the functional outcome of this interaction
has not been explored. Recently, we demonstrated that DENV
NS1 interacts directly with vitronectin (VN), a regulatory protein
that hinders the insertion of the MAC into membranes and
binds the terminal complement proteins C5, C6, C7, and
C9 (Conde et al., 2016). DENV NS1 alone or in association
with VN, inhibited C9 polymerization, thus preventing lytic
pore formation independently from its glycosylation pattern.
Moreover, by binding to C9, mammalian secreted DENV,
WNV, and ZIKV NS1 inhibited MAC formation on cell
membranes. Taken together, these data imply a role of NS1
as a terminal pathway inhibitor of the complement system
(Conde et al., 2016). It is more likely that NS1 acts as a
complement evasion protein during the acute phase of the
disease when anti-NS1 antibodies have not yet formed immune
complexes, providing a less adverse extracellular environment
for the released viruses. In the context of dengue secondary
infections, ADE, immune complex deposition and complement
activation may be critical for the development of severe
cases.
CONCLUDING REMARKS
The complement system certainly influences the outcome of
flavivirus infections. However, we still have only a glimpse of the
mechanisms that orchestrate the protective effects of complement
activation. On the other hand, there are consequences for the host
that arise from complement downregulation by those viruses.
Research in this area will contribute to the current knowledge of
flavivirus pathogenesis, providing insight into the regulation of
immune responses and leading to improved anti-viral inhibitors
and vaccine approaches.
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